Producing cells that reset a damaged immune system

As many as one in 10 people worldwide are affected by autoimmune diseases – but many treatments that manage the symptoms have had inconsistent results and are prohibitively expensive. Professor Huji Xu (PhD(Med) ’95) is the daring doctor who has developed a radical new treatment for autoimmune disease that shows it may be possible to “reset” a damaged immune system and achieve long-term remission.

Disorders occur when rogue immune cells release antibodies that attack the body’s own tissue. Professor Xu, who is Chair of the Department of Rheumatology at Shanghai Changzheng Hospital in China, published the first results of a revolutionary cellular therapy for autoimmune diseases in September 2024, and is now working on cost-effective manufactured cell therapies that are safer, faster to deliver, and more affordable than conventional personalised CAR T treatments, marking a dramatic shift in autoimmune care.

For these great innovations, Professor Xu was named among Nature’s 10, the leading journal’s list of 10 people who shaped science in 2024, and was listed in Time magazine’s Health 100 in 2025 – and he acknowledges that a crucial part of his medical development occurred when he moved to Adelaide in 1990, to complete a PhD in clinical immunology at Flinders University.

Professor Xu trained as a medical doctor in Shanghai, but shared a keen interest in immunology and rheumatology with Flinders University’s Professor Peter Roberts-Thomson, who became supervisor for Professor Xu’s thesis. “Professor Roberts-Thomson was the leading person in that field, and he helped me apply for a scholarship so that I could come and enjoy a fantastic six years at Flinders. I now think of Australia as my second home.”

A central theme of Dr Xu’s research has been unravelling the genetic and cellular mechanisms that drive autoimmune disease, most notably in ankylosing spondylitis, a painful and often disabling inflammatory disease of the spine.

In 2008, he returned to Shanghai and established a large clinical and research centre for rheumatology. Ideas to target the root cause of autoimmune diseases first formed in 2018, but the outbreak of COVID-19 in 2020 temporarily shut down this line of medical research. It recommenced in late 2021, with Professor Xu developing the CAR-T-cell trial from his clinical experience and research interest in the underlying causes of rheumatic disease.

His landmark study, published in 2024, outlined the first use of engineered immune cells from healthy donor cells to target affected cells that are mistakenly attacking the body’s own tissues in autoimmune diseases.

The first patients with autoimmune diseases that Professor Xu worked with on the CAR-T-cell trial were extremely frail. For ethical reasons, they could only be introduced to the radical new cell therapy because all other medicines had failed. He initially feared they may not have the strength to come through the ordeal, but the first patient – a woman suffering from extreme muscle weakness – was able to raise her arms to comb her hair only two weeks after receiving engineered immune cells.

Six months later, the initial three recipients were all in remission. For her most recent check-up, the woman drove 200km from her Hangzhou home to the Shanghai Hospital.

The key development is that Professor Xu’s trial used cells taken from an independent donor, whereas previous trials used cells taken from the person being treated. The donor strategy allows for mass production of CAR-T-cell treatments, which will greatly reduce the costs and be more readily available than traditional CAR-T therapies which rely on a patient’s own cells.

The treatment has now been successfully administered to patients in Professor Xu’s clinics. This builds on the pioneering work of rheumatologist Georg Schett at University Hospital Erlangen in Germany, who first demonstrated the efficacy of autologous CAR-T cell therapy in autoimmune diseases. Based on these expanding trials, Professor Xu is confident the treatment will be available for widespread public use in the coming year.

“The biggest advantage of allogeneic CAR-T is that the product can be industrially mass-produced, which ensures consistent quality while reducing costs,” he says. “I am a physician, so I really want to change our clinical practice to benefit patients – and this serves as the driving force that keeps us moving forward in scientific research.”

 

Professor Huji Xu (PhD(Med) ’95) was awarded the 2026 Convocation Medal for outstanding leadership in pioneering world-first allogeneic CAR-T cell therapy for autoimmune diseases.    

Posted in
2026 Alumni Awards College of Medicine and Public Health Higher Degree Research (PhD) Medicine

Leave a Reply